|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0000932,
umls-concept:C0012854,
umls-concept:C0017262,
umls-concept:C0019682,
umls-concept:C0019699,
umls-concept:C0035804,
umls-concept:C0042210,
umls-concept:C0052712,
umls-concept:C0185117,
umls-concept:C0332307,
umls-concept:C0441513,
umls-concept:C0449432,
umls-concept:C1179435,
umls-concept:C1524073,
umls-concept:C1527177,
umls-concept:C1548799,
umls-concept:C1705248,
umls-concept:C2911684
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2004-7-9
|
|
pubmed:abstractText |
Recombinant modified vaccinia virus Ankara (MVA) expressing SIV or SHIV Gag-Pol and Env, alone or in conjunction with a related DNA vaccine, effectively controls immunodeficiency virus infections in nonhuman primates. Here we describe the construction, characterization, and immunogenicity of MVA/HIV 48, a candidate HIV-1 clade B Gag-Pol-Env vaccine. A novel transfer vector was designed to allow the incorporation of HIV genes regulated by vaccinia virus promoters together with a reporter gene into a single site in the MVA genome and to automatically delete the reporter after the initial isolation of the recombinant MVA. MVA/HIV 48 contains chimeric HIV-1 HXB-2/BH10 gag-pol sequences, a deletion of integrase, inactivating point mutations in reverse transcriptase, and HIV-1 ADA env sequences with a truncation of most of the cytoplasmic domain to enhance expression on the plasma membrane. Cells infected with MVA/HIV 48 expressed HIV proteins, which were processed to the expected size. The Env was inserted into the plasma membrane and was functional in a CCR5 coreceptor-dependent cell fusion assay. Moreover, virus-like particles were released into the medium and budding particles containing Env were visualized by immunoelectron microscopy. Rodents that were immunized with MVA/HIV 48 produced antibodies, which neutralized a heterologous HIV-MN strain, and Gag-specific CD8 T cells. In the accompanying paper, we show that MVA/HIV 48 provided efficient boosting of an HIV DNA vaccine.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0889-2229
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
645-53
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15242542-AIDS Vaccines,
pubmed-meshheading:15242542-Animals,
pubmed-meshheading:15242542-CD8-Positive T-Lymphocytes,
pubmed-meshheading:15242542-Enzyme-Linked Immunosorbent Assay,
pubmed-meshheading:15242542-Gene Deletion,
pubmed-meshheading:15242542-Genes, Reporter,
pubmed-meshheading:15242542-Genes, Viral,
pubmed-meshheading:15242542-Genes, env,
pubmed-meshheading:15242542-Genes, gag,
pubmed-meshheading:15242542-Genes, pol,
pubmed-meshheading:15242542-Guinea Pigs,
pubmed-meshheading:15242542-HIV,
pubmed-meshheading:15242542-HIV Antibodies,
pubmed-meshheading:15242542-Integrases,
pubmed-meshheading:15242542-Mice,
pubmed-meshheading:15242542-Mice, Inbred BALB C,
pubmed-meshheading:15242542-Neutralization Tests,
pubmed-meshheading:15242542-Point Mutation,
pubmed-meshheading:15242542-Protein Structure, Tertiary,
pubmed-meshheading:15242542-RNA-Directed DNA Polymerase,
pubmed-meshheading:15242542-Recombination, Genetic,
pubmed-meshheading:15242542-Simian immunodeficiency virus,
pubmed-meshheading:15242542-Vaccines, DNA,
pubmed-meshheading:15242542-Vaccines, Synthetic
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Multiprotein HIV type 1 clade B DNA and MVA vaccines: construction, expression, and immunogenicity in rodents of the MVA component.
|
|
pubmed:affiliation |
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
